United States RNAi Technology Market is expected to reach US$ 2.2 Billion by 2033 | Top key players - Alnylam Pharmaceuticals, Inc., Thermo Fisher Scientific Inc., Merck KGaA.

Market Size and Growth:

The Global RNAi Technology Market size reached US$ 2.75 Billion in 2024 from US$ 2.51 Billion in 2023 and is expected to reach US$ 6.63 Billion by 2033, growing at a CAGR of 10.4% during the forecast period 2025-2033. The Market is growing due to increasing demand for targeted gene-silencing therapies and rising investments in research for treating genetic and chronic diseases. According to DataM Intelligence

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/rnai-technology-market?sz

The RNAi (RNA interference) Technology Market involves the development and commercialization of RNA-based therapeutics that silence specific genes responsible for diseases. It includes applications in drug discovery, personalized medicine, and biotechnology, focusing on targeting genetic disorders, cancers, and viral infections. The market encompasses RNAi therapeutics, delivery systems, and research tools driving precision medicine advancements.

Industry Recent Developments: United States

✅ October 2025: The growth of RNAi therapeutics in cancer management was highlighted, with the American Cancer Society reporting rising cancer diagnoses and deaths, making RNAi a promising approach for cancer treatments.

✅ November 2025: Advances in AI-driven drug discovery and delivery systems are transforming RNAi technology in the U.S., optimizing target identification and improving therapeutic outcomes, strengthening the U.S. leadership in RNAi innovation.

Industry Recent Developments: Japan

✅ September 2025: The RNAi market in Japan is rapidly growing due to the adoption of precision medicine and personalized healthcare, with successful approvals of RNAi drugs for diverse conditions such as acute hepatic porphyria and hypercholesterolemia, boosting partnerships and pipeline expansions.

✅ October 2025: Japan's biotechnology and biopharmaceutical research sectors continue to expand RNAi applications, fuelled by government funding and strong scientific research infrastructure, supporting growth in drug discovery and development.

✅ November 2025: Japan's vector-based RNAi market is projected to grow significantly, with notable investments by pharmaceutical companies advancing cancer-targeted RNAi therapeutics and improved delivery systems, indicating strong sector momentum.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/rnai-technology-market?sz

FDA Approvals / Regulatory Milestones in 2025:

Qfitlia (fitusiran):

✅ On 28 March 2025, the FDA approved Qfitlia (generic: fitusiran), an siRNA therapeutic, for routine prophylaxis in hemophilia A or B (with or without factor VIII/IX inhibitors).

✅ It works by lowering antithrombin to rebalance clotting (thrombin generation).

✅ Prescribing info confirms its indication and dosing.

✅ This is significant: Qfitlia is the sixth Alnylam-discovered RNAi therapeutic to gain U.S. approval.

AMVUTTRA (vutrisiran):

✅ On 20 March 2025, the FDA approved a supplemental New Drug Application (sNDA) for AMVUTTRA (vutrisiran) to treat cardiomyopathy in transthyretin-mediated amyloidosis (ATTR-CM) in adults.

✅ This expands the drug's indication: previously, vutrisiran was approved for the polyneuropathy form (hATTR-PN), but now it's also approved to reduce cardiovascular mortality, hospitalizations, and urgent heart failure visits.

✅ The FDA label (prescribing information) confirms this cardiomyopathy indication.

Mergers, Acquisitions, and Partnerships:

There's strong deal activity in the RNAi space in 2025, especially around licensing and collaborations:

Novartis ↔ Arrowhead: ARO-SNCA Deal:

✅ In September 2025, Novartis struck a global licensing & collaboration agreement with Arrowhead Pharmaceuticals for ARO‐SNCA, a preclinical siRNA that targets alpha-synuclein (implicated in Parkinson's disease / synucleinopathies).

✅ Arrowhead receives $200 million upfront, plus up to $2 billion in milestone payments, plus royalties.

✅ According to Arrowhead, Novartis will get "exclusive worldwide rights to research, develop, manufacture, and commercialize" using Arrowhead's TRiM platform.

✅ The deal is expected to close in H2 2025, subject to regulatory approvals (e.g., Hart-Scott-Rodino antitrust clearance).

✅ This is a major bet by Novartis on RNAi in neurodegeneration, especially CNS delivery (Arrowhead's platform is designed for subcutaneous delivery to the brain).

Argo Biopharma & Novartis:

✅ Argo Biopharma, a China-based biotech, signed a deal with Novartis in 2025. As per a sector report, Novartis in-licensed two early-stage siRNA candidates from Argo for cardiovascular disease / lipid disorders.

✅ According to market reporting, the deal could be worth up to US$ 5.2 billion, including milestones.

AbbVie & ADARx Pharmaceuticals:

✅ In May 2025, AbbVie and ADARx (which works on siRNA) announced a multi‐billion dollar collaboration to develop next-generation siRNA therapies in neuroscience, immunology, and oncology.

✅ Under the agreement, ADARx got a $335 million upfront payment + potential future payments + royalties.

Kalexo Bio Launch:

✅ A new company, Kalexo Bio, was formed via a licensing deal: Mabwell Bioscience + Aditum Bio are backing Kalexo to develop a dual-target siRNA (2MW7141) for lipid management.

The deal includes potentially up to $1 billion in milestones + tiered royalties.

Major Key Players:

1. Alnylam Pharmaceuticals, Inc. - A pioneer in RNAi therapeutics, developing gene-silencing drugs for rare and genetic diseases worldwide.

2. Thermo Fisher Scientific Inc. - Global leader in scientific instruments, reagents, and services, supporting life sciences research and diagnostics.

3. Merck KGaA - Focused on biopharmaceuticals and life science tools, providing innovative solutions for research and therapeutics.

4. Creative Biolabs - Specializes in custom antibody, protein, and molecular biology services, enabling drug discovery and development.

5. GenScript - Offers gene synthesis, peptide/protein production, and antibody services for research, biopharma, and diagnostics.

6. Revvity - Provides advanced life science and diagnostic solutions, including molecular biology and genomic tools for research.

Segments Covered in the RNAi Technology Market:

By Product Type: siRNA (small interfering RNA), miRNA (microRNA), RNAi Reagents & Kits, Others.

By Therapeutic Application: Rare Genetic Disorders, Oncology, Cardiovascular & Metabolic Disorders, Neurological or Neurodegenerative Disorders, Infectious Diseases, Others.

By End User: Pharmaceutical & Biotech Companies, Academic & Research Institutes, Contract Research Organizations (CROs) & CDMOs, Others.

Regional Analysis for RNAi Technology Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=rnai-technology-market

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, RNAi Technology market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global RNAi Technology Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global RNAi Technology market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the RNAi Technology Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of RNAi Technology market?

➠ Who are the global key manufacturers of the RNAi Technology Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the RNAi Technology market opportunities and threats faced by the vendors in the global RNAi Technology Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the RNAi Technology market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.